Salspera is a clinical-stage biotechnology company committed to developing novel therapies for solid tumor cancers. The company has a platform of microbial immunotherapies that have the potential to address a range of solid tumor cancers where unmet medical need is high. We believe microbial immunotherapies could be used to create a new category of medicines with significant potential to improve the lives of patients.This innovative approach to immunotherapy has been shown to be safe and effective in human clinical trials and through years of published animal studies. We are rapidly advancing our platform of experimental, revolutionary therapies toward approval to reach patients who need them the most. To learn more, please visit www.salspera.com